放疗联合吉西他滨治疗中晚期宫颈癌的临床疗效观察  

Clinical Study of Radiotherapy Combined with Gemcitabine for Patients with Middle-Advanced Stage Cervical Cancer

作　　者：宋丽君[1] 田继刚[2] 武金宝[2] 

机构地区：[1]包头医学院第二附属医院放疗科,014030 [2]包头医学院第二附属医院内蒙古消化病研究所,014030

出　　处：《中国医药指南》2010年第29期178-179,共2页Guide of China Medicine

基　　金：内蒙古自治区高等学校科学研究项目(NJ10183)

摘　　要：目的观察吉西他滨联合放疗治疗中晚期宫颈癌的临床疗效。方法选取包头医学院第二附属医院自2006年1月至2008年12月收治的126例中晚期宫颈癌患者随机分为观察组(联合治疗组)和对照组(单纯吉西他滨治疗组)各63例,观察比较两组的治疗效果。结果观察组CR3例,PR28例,总有效率为49.2%;对照组CR1例,PR12例,总有效率为20.6%。两组比较差异显著(P<0.01),具有统计学意义;观察组骨髓抑制、放射性直肠炎不良反应发生率极高,与对照组相比差异显著(P<0.01)。结论吉西他滨联合放疗治疗中晚期宫颈癌临床效果理想,但应注意治疗过程中不良反应情况。Objective To observe gemcitabine combined radiation to treat cervical cancer middle-late clinical curative effect.Methods From January 2006 to 2008 December of 126 cases of cervical cancer patients in the Second Affiliated Hospital of Baotou Medical College were randomly divided into observation period, combined treatment group （group） and the control group （simple gemcitabine in treatment group）, 63 compare two group of therapeutic effect.Results The observation group, PR 28, CR 3 d-fenders, the total effective rate, CR 1, PR 12 control, the total effective rate was 20.6% （P0.01）, and the observation group marrow inhibition, radiation proctopathy adverse reaction rate is extremely high, in contrast with the significant difference （P0.01）.Conclusion Gemcitabine combined radiation to treat cervical cancer, the clinical effect of ideal period but should pay attention to during the treatment situation adverse reactions.

关 键 词：放疗 吉西他滨 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]